AI Article Synopsis
- Transcatheter arterial chemoembolization (TACE) is beneficial for patients with unresectable hepatocellular carcinoma (HCC), and this study explores the effects of adding external beam radiation therapy (EBRT) with concurrent chemotherapy.
- The research involved 44 patients treated with TACE, with 7 also receiving EBRT; results showed that combined treatment significantly increased mean transplant-free survival times (TACE alone: 376 days vs. TACE + EBRT: 879 days).
- The findings suggest that combining EBRT and chemotherapy with TACE is manageable and effective, highlighting the need for further studies on overall survival benefits from this treatment approach.
Article Abstract
Background: Transcatheter arterial chemoembolization (TACE) improves survival in patients with unresectable hepatocellular carcinoma (HCC). Partial liver radiotherapy with modern techniques has been shown to be safe. The purpose of this study was to evaluate the survival value of external beam radiation therapy (EBRT) with concurrent chemotherapy combined with TACE.
Methods: A University of Virginia Interventional Radiology patient log was used to identify patients treated with TACE ± another modality from 1999 through 2005. During this time, 44 patients received TACE for unresectable HCC, and 7 of these received adjuvant EBRT. Univariate analysis and multivariable proportional hazards survival modeling were used to identify factors impacting survival.
Results: We compared 37 patients receiving TACE alone to 7 receiving TACE and EBRT (5 with concurrent capecitabine). Unadjusted mean transplant-free survival times were TACE only = 376 days (standard error [SE] = 63 days), TACE + EBRT = 879 days (SE = 100 days). EBRT, TNM stage, and MELD score were important predictors for survival on univariate analysis (p < .10). The adjusted hazard ratio for transplant or death in the TACE + EBRT group was 0.15 (0.02-0.95, p = .026).
Conclusion: EBRT with concurrent chemotherapy following TACE is feasible and well tolerated with modern treatment techniques. Further research should be directed toward determining the potential overall survival benefit of adjuvant EBRT with chemotherapy following TACE for hepatocellular carcinoma.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3348711 | PMC |
Publication Analysis
Top Keywords
Similar Publications
PSA bounce: understanding temporal fluctuations in prostate cancer after external radiotherapy.
Clin Transl Oncol
December 2024
Department of Medicine, School of Medicine and Haalth Sciences, Universitat Internacional de Catalunya, Josep Trueta s/n, 08195, Sant Cugat del Vallès, Spain.
Purpose: Prostate-specific antigen (PSA) bounce is a transient elevation in PSA levels commonly observed after radiotherapy. This study aims to investigate the characteristics, timing, and clinical implications of PSA bounce (PSA-B) in prostate cancer patients treated with external beam radiotherapy (EBRT), exploring potential causes and its relevance in patient management.
Materials And Methods: Between 2013 and 2019, 629 patients with localized prostate cancer were treated with EBRT.
Patterns of Care, Prognostic Factors, and Survival Outcomes for Patients of Cervical Carcinoma: A Study From North India.
Cureus
October 2024
Department of Radiation Oncology, Indira Gandhi Medical College, Shimla, IND.
Objectives: Cervical cancer is the second most common malignancy among Indian women after breast cancer. This study was undertaken to determine the pattern of care, long-term survival outcomes, and prognostic factors for cervical cancer patients treated at a tertiary care cancer centre in North India.
Methods: Ten-year data was retrieved for 435 stage I-IVA carcinoma cervix patients treated between 2009 and 2019.
A phase III randomised trial on the addition of a contact X-ray brachytherapy boost to standard neoadjuvant chemo-radiotherapy for organ preservation in early rectal adenocarcinoma: 5 year results of the OPERA trial.
Ann Oncol
November 2024
Centre Antoine Lacassagne, Université Côte d'Azur, Nice, France.
Background: The OPERA trial has shown that a contact X-ray brachytherapy 50 kV (CXB) boost with neoadjuvant chemoradiotherapy (NCRT) can increase organ preservation (OP) rate for early rectal adenocarcinoma (ADK) of low-mid rectum. We report the results after 5 years of follow-up.
Patients And Methods: OPERA was a multicentre, phase III trial that included operable patients (pts), with cT2-cT3b low-mid rectal ADK, tumours <5 cm, cN0 or cN1 <8 mm.
Treating a Refractory Locally Advanced Carcinoma of the Cervix With Cone-Beam Computed Tomography-Based Adaptive External Beam Radiotherapy: A Case Report.
Cureus
September 2024
Radiation Oncology, Meherbai Tata Memorial Hospital, Jamshedpur, IND.
Adaptive radiotherapy (ART) refers to methods that allow a radiation therapy plan to be adjusted based on images obtained during the treatment. Using cutting-edge imaging methods such as computed tomography (CT), magnetic resonance imaging (MRI), and positron emission tomography (PET), ART can adjust the treatment plan in response to observed changes in anatomy and even biology while the patient is receiving treatment. The backbone of ART is intensity-modulated RT (IMRT), which permits better sparing of normal critical organs while still delivering a uniform dose to target tumor volume.
View Article and Find Full Text PDFFirst Application of Demand-Triggered Online Adaptive Radiotherapy in the Treatment of Cervical Cancer: A Clinical Report.
Cureus
September 2024
Department of Radiation Oncology, The First Affiliated Hospital of Soochow University, Suzhou, CHN.
Article Synopsis
- Adaptive radiation therapy (ART) offers significant advantages in treating gynecological cancers due to factors like organ motion and deformation, with types including offline, online, and real-time methodologies.
- The introduction of on-demand online adaptive radiotherapy (OART) addresses issues of treatment precision and timing, showcasing its effectiveness in two cervical cancer patients undergoing different radiation treatments.
- Both patients experienced improved target volume coverage and lower doses to surrounding organs with OART, resulting in manageable side effects during treatment, with no severe toxic reactions reported.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!